|
|
|
시장보고서
Drug Delivery Technologies: Nano-enabled Delivery Players, products & prospects to 2018
|
Abstract
The true value of nanotechnology lies in its potential to improve the
solubility and enhance the efficiency of product delivery. It has been
successfully applied to the commercialisation of more than 30 drugs.
Regulators have published numerous white papers on the topic and established
Task Forces to monitor the progress and application of this technology
although there are presently no regulations specific to nanomedicine or
nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms
emerge to address the industry' s need for therapeutic, bioavailable and less
toxic products, this market is expected to grow significantly over the next
decade. Proof of concept data with novel compounds is accumulating and new
formulations of old chemotherapeutic drugs offer the promise to revolutionise
cancer therapies.
The potential of future applications:
- Tissue specific delivery - targeting the delivery of small and macro
molecules across biological membranes such as the blood brain barrier for CNS
drugs;
- Gene and vaccine delivery - non-viral delivery of genetic materials in
nanohydrogels and nanocarriers with a high degree of efficiency and expression;
- Controlled-release devices - design of new nanoporous, bioerodible
membranes;
- Increased biocompatibility - design of artificial surfaces engineering
for medical and dental implants to by-pass unwanted inflammatory response;
- Improved drug bioavailability and solubility - through the engineering
of drugs and reagents by nanostructuring;
- Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for
the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion.
The market will mature as the number of marketed nano-enabled products
doubles and second generation nanomedicines begin to emerge. These agents
will address areas of high unmet clinical need and result in the formulation
of approved and novel drugs which are safer, less toxic and more efficacious
than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly
US$2.9 billion and establish nanotechnology as an important tool in the
industry' s delivery armoury. A range of proprietary delivery platforms will
utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles
to target a number of therapy areas such as CNS disorders, oncology and
infectious diseases.
This report is part of a major new 4-volume strategic analysis
- VOLUME I: CONTROLLED- RELEASE
- VOLUME II: NANOTECHNOLOGY
- VOLUME III: NUCLEIC ACID DELIVERY
- VOLUME IV: TARGETED DELIVERY
Table of Contents
EXECUTIVE SUMMARY & INTRODUCTION
- Overview of nanotechnology: past, present & future
- Nanotechnology: motivators & resistors
- Nanomedicines, formulations and product regeneration
NANOTECHNOLOGY IN DRUG DELIVERY
- Core nanotechnology used by the pharma industry
- Nano-engineered drugs
- Nano-carriers: Dendrimer, liposome micelle and polymeric nanoparticle
structures
- Current therapeutic applications of nanotechnology in drug delivery
- Leading brands that utilise nanotechnology delivery
- Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading nanotechnology drug delivery companies
- Strategic development & commercialisation partnerships and joint ventures
- Mergers, acquisitions, start-ups & spin offs
- Intellectual property
THE CURRENT & FUTURE MARKET
- Leading approved nano-enabled product sales 2009
- Companies developing nano-enabled product sales 2009
- Novel nano-enabled product sales 2018
- Global nano-enabled product sales 2018
COMPETITOR ANALYSIS
Detailed analysis of leading companies covering:
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products using the delivery technology
- Competitor ratio analysis
Companies analysed
- Abraxis BioScience, Inc
- Access Pharmaceuticals, Inc
- AlphaRx Corporation
- ALZA Corporation
- Aphios Corporation
- Applied Pharma Research S.A.
- BioSante Pharmaceuticals, Inc
- Calando Pharmaceuticals, Inc
- Camurus A.B.
- Cerulean Pharma, Inc
- CytImmune Sciences, Inc
- Elan Corporation, Plc
- Enzon Pharmaceuticals, Inc.
- Gilead Sciences, Inc
- Introgen Therapeutics
- Mersana Therapeutics
- Nano Interface Technology
- Nano S Biotechnology GmbH
- NanoBio Corporation
- NanoBioMagnetics, Inc
- Nanobiotix, Inc
- NanoCarrier, Inc
- Nanotechnology Victoria, Ltd.
- NanoMaterials Technology
- Nanotherapeutics, Inc
- Novavax, Inc.
- SkyePharma, Plc
- Spherics Pharmaceuticals, Inc
- Starpharma Holdings, Ltd
APPENDICIES
- Nanotechnology approved drug sales 2008-2018
- Nanotechnology developmental drug sales 2008-2018
- Key nanotechnology delivery companies by 2018
|
 |
